Delving into the Latest Updates on Clopidogrel napadisilate with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Clopidogrel, Clopidogrel napadisilate monohydrate, Pidogul

+ [1]

Target

P2Y12 receptor

Action

antagonists

Mechanism

P2Y12 receptor antagonists(Purinergic receptor P2Y12 antagonists)

Therapeutic Areas

Cardiovascular Diseases

Active Indication

Thrombosis

Inactive Indication-

Originator Organization

Hanmi Pharmaceutical Co., Ltd.

Active Organization

Hanmi Pharmaceutical Co., Ltd.

Inactive Organization-

License Organization-

Drug Highest PhaseApproved

First Approval Date

United Kingdom (23 Dec 2010),

Thrombosis

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC16H16ClNO2S

InChIKeyGKTWGGQPFAXNFI-HNNXBMFYSA-N

CAS Registry113665-84-2

View All Structures (2)

Patients on dual antiplatelet therapy )aspirin plus a P2Y12 inhibitor [clopidogrel, prasugrel, or ticagrelor]) undergoing screening or surveilance colonoscopy are at increased risk for bleeding from the procedure. Patients are ussually asked to stop the P2Y12 inhibitor for the procedure. Currently, recommendation is that patients only on a P2Y12 inhibitor be changes to aspirin for the procedure. This pilot study will evaluate if there is a large difference in bleeding between patients only taking aspirin compared with patients only taking a P2Y12 inhibitor. Patinets who participate will randomly be randomly asked to stop either aspirin or the P2Y12 inhibitor 1 week before the procedure. Periprocedural bleeding and bleeding after the procedure for iup to 30 days.

Start Date01 Oct 2024

Sponsor / Collaborator-

100 Clinical Results associated with Clopidogrel napadisilate

Login to view more data

100 Translational Medicine associated with Clopidogrel napadisilate

Login to view more data

100 Patents (Medical) associated with Clopidogrel napadisilate

Login to view more data

10,096

Literatures (Medical) associated with Clopidogrel napadisilate

01 May 2025·Journal of Pharmaceutical and Biomedical Analysis

Simultaneous quantification of eighteen therapeutic oral anticoagulants, rodenticides, and antiplatelet agents by LC-MS/MS and its application in post-mortem forensic cases

Article

Author: Delavenne, Xavier ; Bidat, Carolyne ; Escal, Jean ; Hodin, Sophie ; Duband, Sébastien ; Drague, Angélique ; Dellinger, Sandrine ; Feliu, Catherine

Anticoagulants and antiplatelet agents, which interfere with blood coagulation, can lead to fatal bleeding. Moreover, their widespread use as drugs or rodenticides poses a high risk of accidental or intentional poisoning. Therefore, quantifying these substances is essential in forensic investigations. This research aimed to develop and validate a liquid chromatography-tandem mass spectrometry method capable of quantifying eighteen anticoagulant or antiplatelet compounds (apixaban, rivaroxaban, dabigatran, warfarin, acenocoumarol, fluindione, brodifacoum, bromadiolone, difenacoum, difethialone, chlorophacinone, coumatetralyl, flocoumafen, acetylsalicylic acid, clopidogrel, dipyridamole, ticagrelor, and ticlopidine) in a single run with simple sample preparation. The method was validated according to the FDA recommendations for all compounds, with an eight-min run time in human whole blood, the gold standard in toxicological forensic investigation. The method was also validated for therapeutic compounds and most rodenticides in bile and vitreous humor. Following validation, the method was applied to seven forensic cases with a known history of anticoagulant or antiplatelet agent use to prove the validity of the method. This method provides a valuable tool for legal contexts where precise determination of anticoagulant compound presence and concentration is required.

03 Apr 2025·International Journal of Neuroscience

Effect of atorvastatin calcium plus clopidogrel in the treatment of patients with transient ischemic attacks and its effect on blood lipids and platelets

Article

Author: Bian, Maocheng ; Wan, Jian ; Zhong, Fei

OBJECTIVETo explore the clinical effect of atorvastatin calcium combined with clopidogrel in the treatment of patients with transient ischemic attacks (TIAs) and its effect on blood lipids and platelets.METHODSLow-density lipoprotein cholesterol (LDL-C)], platelet-related parameters [prothrombin time (PT), activated partial thromboplastin time (APTT), platelet count (PLT)], incidence of cerebral infarction, and adverse reactions.RESULTSThe clinical outcomes of the experimental group patients were significantly better than those of the control group patients (p < 0.05). The experimental group exhibited notably lower levels of TG, TC, and LDL-C compared to the control group (p < 0.05). Platelet-related indices-PT, APTT, and PLT-showed no significant differences between groups before and after treatment (p > 0.05). The incidence of cerebral infarction was notably lower in the experimental group (p < 0.005), while the occurrence of adverse reactions showed no significant difference between groups (p > 0.05).CONCLUSIONAtorvastatin calcium combined with clopidogrel demonstrates a positive impact on individuals with TIAs by significantly lowering levels of LDL, total cholesterol, and triglycerides. However, it is noteworthy that platelet-related indices did not exhibit significant differences between the experimental and control groups. While the observed improvements in blood lipids are attributed to the effects of atorvastatin, the combination with clopidogrel did not show a substantial influence on platelet-related parameters. Thus, the overall therapeutic impact, particularly on platelet-related indices, may require further investigation and clarification. Despite these nuances, our findings suggest potential benefits in reducing the risk of adverse reactions and cerebral infarction, supporting the consideration of this approach for wider clinical use.

24 Mar 2025·Angewandte Chemie International Edition

Universal Reagent for Mild and Stereospecific Nucleophilic Substitution of Alcohols with Amines

Article

Author: Dauphinais, Maxime ; Sagamanova, Irina K. ; Thai‐Savard, Léa ; Noël, Charlotte ; Régnier, Sophie ; Bechara, William S. ; Charette, André B. ; Jarvis, Scott B. D.

AbstractA user‐friendly reagent for mild and general activation of alcohols towards bimolecular nucleophilic substitution (SN2) leveraging diverse nucleophiles, including primary and secondary amines is reported herein. The new ion‐paired reagent discovery was based upon the putative zwitterionic betaine intermediate of the Mitsunobu reaction and enabled the one‐step conversion of enantioenriched alcohols to valuable chiral C−X bonds (where X=N, C, S, O or halide). The described activating reagent has also been applied to a one‐step methylation reaction using methanol and to an intermolecular amination/intramolecular cyclization sequence that generates heterocycles, such as tetrahydroisoquinolines. This work provides the first evidence by X‐ray crystallography of a protonated betaine as intermediate in the Mitsunobu reaction.

100 Deals associated with Clopidogrel napadisilate

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	Clopidogrel napadisilate	B01AC04	DB00758

R&D Status

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Thrombosis	United Kingdom	Hanmi Pharmaceutical Co., Ltd.	23 Dec 2010

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ACS-DM Registry (ESC2023)	Not Applicable	Acute Coronary Syndrome \| Diabetes Mellitus	539	Ticagrelor	stxndssdkl(rljvxxqpsb): HR = 2.53 (95% CI, 1.32 - 4.84), P-Value = 0.684 View more	Negative	27 Aug 2023
				Clopidogrel
ALPHEUS Naive sub-study (ESC2023)	Not Applicable	Angina, Unstable	1,882	Ticagrelor	loazmjbgim(udqwbuwuti) = layvfzetzg hnwbbvdziy (qexgzmihdg ) View more	-	26 Aug 2023
				Clopidogrel	loazmjbgim(udqwbuwuti) = suqumhjpob hnwbbvdziy (qexgzmihdg ) View more
ALPHEUS study (ESC2023)	Not Applicable	Angina, Unstable	1,866	Ticagrelor	sjfqrofppd(vbelnvpkvk) = wdfoqtzcuk fwlzviqnqw (ocsnugvsrc ) View more	-	26 Aug 2023
				Clopidogrel	sjfqrofppd(vbelnvpkvk) = ewpjaejzxj fwlzviqnqw (ocsnugvsrc ) View more
HOST-EXAM Extended (ESC2023)	Not Applicable	Hemorrhage \| Thrombosis Maintenance	-	Clopidogrel	modwrfstfj(nplebodjxi): HR = 2.7 (95% CI, 2.29 - 3.18)	-	26 Aug 2023
				Aspirin
CREA ARIAM Andalucia registry (ESC2022)	Not Applicable	Acute Coronary Syndrome	2,070	Ticagrelor	bluaezjiyp(jndiggecfm) = rthhtxihmk qhvuopkrql (dvscuomxwq )	-	29 Aug 2022
				Clopidogrel	bluaezjiyp(jndiggecfm) = szfzcboxsv qhvuopkrql (dvscuomxwq )
ESC2022	Not Applicable	Acute Coronary Syndrome	-	Clopidogrel SAPT	(lidiaroxjl): HR = 0.72 (95% CI, 0.54 - 0.98)	-	28 Aug 2022
				Aspirin monotherapy
ESC2022	Not Applicable	Acute Coronary Syndrome	-	Ticagrelor	(neeqhpewqy): HR = 0.9 (95% CI, 0.84 - 0.97) View more	-	27 Aug 2022
				Clopidogrel
CREA ARIAM Andalucia registry (ESC2022)	Not Applicable	Acute Coronary Syndrome	2,070	Ticagrelor	(fyuagfpeqe): adjusted hazard ratio = 1.4 (95% CI, 0.96 - 2.05)	-	19 Mar 2022
				Clopidogrel
CREA-ARIAM Andalucia registry (ESC2022)	Not Applicable	Acute Coronary Syndrome	2,070	Ticagrelor	xxhgvlkcrz(vkefzksdhq) = fgaeckzeit oklnkvrgvq (gavlunpouy )	-	18 Mar 2022
				Clopidogrel	xxhgvlkcrz(vkefzksdhq) = vzuasytpkw oklnkvrgvq (gavlunpouy )
ISC2022	Not Applicable	-	-	Clopidogrel bolus	dglmnndxbu(uyicawtmyw) = midfrmnpvc uvhjlpyjlc (yjdliwczkl ) View more	Negative	01 Feb 2022
				Sustained clopidogrel pre-treatment	dglmnndxbu(uyicawtmyw) = dlobbfeohv uvhjlpyjlc (yjdliwczkl ) View more